Sign in
Taking people in United StatesPhase 3

Deuruxolitinib for teenagers with severe alopecia areata, compared with placebo

Tests deuruxolitinib against placebo in teenagers with severe alopecia areata.

Key facts

Who runs it
Sun Pharmaceutical Industries, Inc.
Where
Auburn Hills, Bakersfield, Birmingham, Boise, Bryant, Cary, Charlotte, Chicago, Clarksville, Cumming, Dallas, Denver, Doral, Fremont, Frisco, Greenville, Hollywood, Indianapolis, Kissimmee, Los Angeles, Louisville, Lynnwood, Macon, Mason, Miami, Miami Lakes, Missoula, Omaha, Palm Springs, Pflugerville, Plymouth Meeting, Pompano Beach, Rockville, Saint Joseph, San Antonio, San Diego, Sanford, Savannah, Scottsdale, Smyrna, South Jordan, Springville, Sweetwater, Troy, Verona, Wheat Ridge, and Woodbury, United StatesSee the 54 sitesAlso in 1 other country, 10 sites
Trial code
Registry title
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Status
Recruiting
Phase
Phase 3
People taking part
355 people, planned
Started
5 Aug 2025
Expected to end
May 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Deuruxolitinib
  • Placebo
Record updated
28 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for teenagers aged 12 to under 18 with severe alopecia areata, a condition causing patchy hair loss. They must have lost at least 50% of their scalp hair.

Age
12 to <18 years (12 to 17 years)
Sex
All sexes
Disease stage
Severe alopecia areata with at least 50% scalp hair loss (SALT score ≥50). The current episode must have lasted at least 6 months and not more than 10 years.
Earlier treatment
No medicines or agents that may affect hair regrowth or the immune response within 28 days before the start or during the study.

Main reasons for not taking part

  • Active scalp inflammation, psoriasis or seborrheic dermatitis needing scalp creams, or other scalp problems that affect hair loss scoring
  • Significant scalp injury or untreated actinic keratosis (rough sun-damaged skin patches)
  • Pregnant or breastfeeding, or planning pregnancy during the study and for 30 days after the last dose
  • Serious medical, mental health or social conditions that the study doctor judges would make taking part unsafe or unreliable

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years
  • Between 12 to <18 years of age
  • At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50
  • Willing to comply with the study visits and requirements of the study protocol

Who cannot take part

  • Treatment with other medications or agents within 28 days of Baseline or during the study that may affect hair regrowth or immune response
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug
  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis at Screening and/or Baseline
  • Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 12 and 17 years old?

Where in United States

Also in 1 other country, 10 sites

  • Oakland Hills DermatologyAuburn Hills, United StatesContact: Head Regulatory AffairsTaking people
  • Kern Research, IncBakersfield, United StatesContact: Head Regulatory AffairsTaking people
  • Total Skin and Beauty Dermatology CenterBirmingham, United StatesContact: Head Regulatory AffairsTaking people
  • ASR, LLCBoise, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatology Trial AssociatesBryant, United StatesContact: Head Regulatory AffairsTaking people
  • Revival Research Institute, Llc - Cary, NcCary, United StatesContact: Head Regulatory AffairsTaking people
  • Darst DermatologyCharlotte, United StatesContact: Head Regulatory AffairsTaking people
  • DeNova ResearchChicago, United StatesContact: Head Regulatory AffairsTaking people
  • Ds Research - IndianaClarksville, United StatesContact: Head Regulatory AffairsTaking people
  • Cleaver Medical Group DermatologyCumming, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatology Treatment and Research Center - DallasDallas, United StatesContact: Head Regulatory AffairsTaking people
  • Colorado Medical Research CenterDenver, United StatesContact: Head Regulatory AffairsTaking people
  • D&H Doral Research CenterDoral, United StatesContact: Head Regulatory AffairsTaking people
  • Center For Dermatology Clinical Research, Inc.Fremont, United StatesContact: Head Regulatory AffairsTaking people
  • North Texas Center for Clinical ResearchFrisco, United StatesContact: Head Regulatory AffairsTaking people
  • Tribe Clinical Research LLCGreenville, United StatesContact: Head Regulatory AffairsTaking people
  • Skin Care Research, Llc - HollywoodHollywood, United StatesContact: Head Regulatory AffairsTaking people
  • Dawes Fretzin Clinical Research Group, LLCIndianapolis, United StatesContact: Head Regulatory AffairsTaking people
  • Ilumina Medical Research LLCKissimmee, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatology Research AssociatesLos Angeles, United StatesContact: Head Regulatory AffairsTaking people
  • Ds Research - KentuckyLouisville, United StatesContact: Head Regulatory AffairsTaking people
  • National Eagle Research, LlcLynnwood, United StatesContact: Head Regulatory AffairsTaking people
  • Skin Care Physicians of GeorgiaMacon, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatologists of Southwest OhioMason, United StatesContact: Head Regulatory AffairsTaking people
  • Advance Research Center, LlcMiami, United StatesContact: Head Regulatory AffairsTaking people
  • All X Ray Diagnostic Services CorpMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Florida International Medical ResearchMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Florida Pharmaceutical Research And Associates, Inc.Miami, United StatesContact: Head Regulatory AffairsTaking people
  • L&C Professional Medical Research InstituteMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Millennium Medical Research LLCMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Pediatric Skin Research LlcMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Valencia Medical & Research CenterMiami, United StatesContact: Head Regulatory AffairsTaking people
  • Barroso Medical Services LlcMiami Lakes, United StatesContact: Head Regulatory AffairsTaking people
  • Boeson Research MSOMissoula, United StatesContact: Head Regulatory AffairsTaking people
  • Skin Specialists, PCOmaha, United StatesContact: Head Regulatory AffairsTaking people
  • Palmtree Clinical ResearchPalm Springs, United StatesContact: Head Regulatory AffairsTaking people
  • Austin Institute for Clinical Research, Inc.Pflugerville, United StatesContact: Head Regulatory AffairsTaking people
  • Dermatology Associates of Plymouth MeetingPlymouth Meeting, United StatesContact: Head Regulatory AffairsTaking people
  • Nexus Research LlcPompano Beach, United StatesContact: Head Regulatory AffairsTaking people
  • U.S. Dermatology Partners RockvilleRockville, United StatesContact: Head Regulatory AffairsTaking people
  • Medisearch Clinical TrialsSaint Joseph, United StatesContact: Head Regulatory AffairsTaking people
  • Texas Dermatology and Laser SpecialistsSan Antonio, United StatesContact: Head Regulatory AffairsTaking people
  • Paradigm Clinical Research - San DiegoSan Diego, United StatesContact: Head Regulatory AffairsTaking people
  • International Clinical Research Us Llc - SanfordSanford, United StatesContact: Head Regulatory AffairsTaking people
  • Georgia Skin & Cancer ClinicSavannah, United StatesContact: Head Regulatory AffairsTaking people
  • Avacare - Cct Research - Center For Dermatology And Plastic SurgeryScottsdale, United StatesContact: Head Regulatory AffairsTaking people
  • Delricht Research - SmyrnaSmyrna, United StatesContact: Head Regulatory AffairsTaking people
  • Jordan Valley DermatologySouth Jordan, United StatesContact: Head Regulatory AffairsTaking people
  • Avacare - Cct Research - Springville DermatologySpringville, United StatesContact: Head Regulatory AffairsTaking people
  • LENUS Research & Medical Group, LLCSweetwater, United StatesContact: Head Regulatory AffairsTaking people
  • Revival Research Institute, Llc - Troy, MiTroy, United StatesContact: Head Regulatory AffairsTaking people
  • Schweiger Dermatology & Allergy - VeronaVerona, United StatesContact: Head Regulatory AffairsTaking people
  • Paradigm Clinical Research - Wheat RidgeWheat Ridge, United StatesContact: Head Regulatory AffairsTaking people
  • Vitality Clinical TrialsWoodbury, United StatesContact: Head Regulatory AffairsTaking people

About the trial

What the trial wants to find out

This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.

The 3 groups in the trial

  • Treatment Period: Deuruxolitinib 8 mgTreatment being tested

    Deuruxolitinib tablets, orally, twice daily (BID) for up to 24 weeks

    Treatment: Deuruxolitinib

  • Treatment Period: PlaceboPlacebo, for comparison

    Deuruxolitinib-matched placebo tablets, orally, BID for up to 24 weeks

    Treatment: Placebo

  • Open-Label Extension: Deuruxolitinib 8 mg BIDTreatment being tested

    Deuruxolitinib tablets, orally, BID for up to 52 weeks

    Treatment: Deuruxolitinib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescent Patients With Severe Alopecia Areata With an Open-label Extension Period
Plain-language title
Deuruxolitinib for teenagers with severe alopecia areata, compared with placeboGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07133308, who can take part
Record updated
28 January 2026